CD20 (Clusters of Differentiation 20) inhibitors
- Name
- CD20 (Clusters of Differentiation 20) inhibitors
- Accession Number
- DBCAT005729
- Description
Not Available
- ATC Classification
- Drugs
Drug Drug Description Rituximab A monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis. Ofatumumab An anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications. Obinutuzumab An antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil. - Drugs & Drug Targets
Drug Target Type Rituximab B-lymphocyte antigen CD20 target Ofatumumab B-lymphocyte antigen CD20 target Obinutuzumab B-lymphocyte antigen CD20 target